Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2025-12-10 | 2025-12-10 |
| Drug Identification Number | 02517663 | 02517663 |
| Brand name | PENTAMIDINE ISETIONATE FOR INJECTION BP | PENTAMIDINE ISETIONATE FOR INJECTION BP |
| Common or Proper name | PENTAMIDINE FOR INJECTION 300MG/VIAL | PENTAMIDINE FOR INJECTION 300MG/VIAL |
| Company Name | MARCAN PHARMACEUTICALS INC | MARCAN PHARMACEUTICALS INC |
| Ingredients | PENTAMIDINE ISETIONATE | PENTAMIDINE ISETIONATE |
| Strength(s) | 300MG | 300MG |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR | INTRAVENOUS INTRAMUSCULAR |
| Packaging size | PACK X 5 VIALS | PACK X 5 VIALS |
| ATC code | P01CX | P01CX |
| ATC description | AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS | AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS |
| Reason for shortage | Delay in shipping of the drug. | Delay in shipping of the drug. |
| Anticipated start date | 2025-12-11 | 2025-12-11 |
| Actual start date | 2025-12-11 | 2025-12-11 |
| Estimated end date | 2026-01-15 | 2026-01-15 |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Marcan regrets to advise that due to production delays, there will be a temporary supply interruption for this product. Limited inventory remains available at CPDN and McKesson; however, all stock is currently subject to full preventative allocation. | Marcan regrets to advise that due to production delays, there will be a temporary supply interruption for this product. Limited inventory remains available at CPDN and McKesson; however, all stock is currently subject to full preventative allocation. |
| Health Canada comments |